type: pattern tags: [dilution, bank, fintech, tbv, equity-raise, capital-structure, bank-licensed] confidence: medium created: 2026-03-31 source: SOFI earnings-review Q4_FY25 persona: gaucho provenance: legacy source_analysis_path: null source_paragraph_quote: null source_transcript_span: null source_loss_log_path: null

Equity Raise Dilution Mispricing: TBV/Share Accretion as the True Test

For bank-licensed entities and book-value-anchored businesses, share count growth overstates dilution harm when equity is raised at a premium to tangible book value and deployed productively. The correct dilution test is TBV/share trajectory, not share count trajectory. If TBV/share compounds faster than shares are issued, the equity raise is accretive at the fundamental level — and any market sell-off driven purely by share count growth is a mispricing.

Evidence

• SOFI FY25: share count +17% YoY from capital raises. TBV/share simultaneously rose from $4.47 → 7.01, +57( 110M annual interest savings). Each raise was executed at a significant premium to then-current TBV, making it mechanically accretive to per-share book value.
• The dilution narrative (shares +17%) and the fundamental reality (TBV/share +57%) pointed in opposite directions. Investors anchored on share count faced a stock moving from a Nov 2025 peak of $32.50 to $16.90 in Mar 2026 — a 48% discount — while the underlying book value per share was at an all-time high.

Implication

When analyzing bank-licensed or book-value-anchored companies with visible share count growth, apply a three-part accretion test before weighting dilution as a risk:

1. Premium to TBV? — equity raised above current TBV/share is mechanically accretive
2. Productive deployment? — proceeds fund debt reduction or earning assets (not losses)
3. TBV/share compounding? — confirm TBV/share is rising despite the share issuance

If all three pass, downgrade the dilution concern from "structural risk" to "watch item" and reframe as value-creative capital deployment. The most telling signal is when TBV/share growth rate materially exceeds EPS growth rate — this indicates reinvestment compounding that forward P/E multiples will understate. Existing dilution insights (ATM headline overstating committed dilution; SBC trajectory) address different mechanisms; this test applies specifically to equity capital raises in regulated entities with book value accounting.